Study of step-down therapy from formoterol/budesonide combinations in patients with asthma

Study of step-down therapy from formoterol/budesonide combinations in patients with asthma - Step-down therapy from formoterol/budesonide combinations

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010333

Enrollment

150

Registered

2013-03-27

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Interventions

Switch from budesonide/formoterol (Symbicort)160/4.5ug two inhalation twice daily to one inhalation twice daily for 12 weeks Switch from budesonide/formoterol (Symbicort)160/4.5ug two inhalation twice

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Ability and willingness to provide informed consent Budesonide/formoterol (Symbicort) 160/4.5ug two inhalation twice daily at constant dose for 2 months Achieve good control of the GINA criteria

Exclusion criteria

Exclusion criteria: History of presence of lung, cardiac, renal and liver disease

Design outcomes

Primary

Measure	Time frame
Asthma attack during the treatment period	—

Secondary

Measure	Time frame
Lung function during the treatment period QOL score during the treatment period FeNO during the treatment period Adverse events during the treatment period	—

Countries

Japan

Contacts

Public ContactDai Hashimoto

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

dai@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026